|
1.
|
|
9 p, 1.4 MB |
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features
/
Font, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domenech, Montserrat (Althaia Xarxa Assistencial Universitària de Manresa) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Marqués, Miriam (Centro Nacional de Investigaciones Oncológicas) ;
Benítez, Raquel (Centro Nacional de Investigaciones Oncológicas) ;
Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gago, José L. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sant, Francesc (Althaia Xarxa Assistencial Universitària de Manresa) ;
Lopez, Hector (Althaia Xarxa Assistencial Universitària de Manresa) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Malats, Núria (Centro Nacional de Investigaciones Oncológicas) ;
Calle, M. Luz (Universitat de Vic - Universitat Central de Catalunya) ;
Real, Francisco X. (Universitat Pompeu Fabra)
Background and objective: Neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care in muscle-invasive bladder cancer (MIBC). Pathological response has been associated with longer survival, but no currently available clinicopathological variables can identify patients likely to respond, highlighting the need for predictive biomarkers. [...]
2023 -  10.3389/fonc.2023.1155244
Frontiers in Oncology, Vol. 13 (august 2023)
|
|
|
2.
|
|
19 p, 1.6 MB |
Strategies to design clinical studies to identify predictive biomarkers in cancer research
/
Perez-Gracia, Jose Luis (Clínica Universidad de Navarra) ;
Sanmamed, Miguel F. (Yale University School of Medicine) ;
Bosch, Ana (Lund University) ;
Patiño-Garcia, Ana (Clínica Universidad de Navarra) ;
Schalper, Kurt A. (Yale School of Medicine) ;
Segura, Victor (Universidad de Navarra) ;
Bellmunt, Joaquim (Dana-Farber Cancer Institute and Harvard Medical School) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Sweeney, Christopher J. (Dana-Farber Cancer Institute and Harvard Medical School) ;
Choueiri, Toni K. (Dana-Farber Cancer Institute and Harvard Medical School) ;
Martín Jiménez, Miguel (Hospital Gregorio Marañón. Instituto de Investigación Sanitaria) ;
Fusco, Juan Pablo (Clínica Universidad de Navarra) ;
Rodriguez-Ruiz, Maria Esperanza (Universidad de Navarra) ;
Calvo, Alfonso (Universidad de Navarra) ;
Prior, Celia (Universidad de Navarra) ;
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Pio, Ruben (Universidad de Navarra) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia) ;
Gonzalez Hernandez, Alvaro (Clínica Universidad de Navarra) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Piulats, Jose María (Institut Català d'Oncologia) ;
Gurpide, Alfonso (Universidad de Navarra) ;
Andueza, Mapi (Clínica Universidad de Navarra) ;
de Velasco, Guillermo (Dana-Farber Cancer Institute and Harvard Medical School) ;
Pazo, Roberto (Hospital Universitario Miguel Servet (Saragossa)) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Nicolas, Pilar (Universidad del País Vasco) ;
Abad-Santos, Francisco (Instituto de Investigación Sanitaria la Princesa (IP)) ;
Garcia-Donas, Jesus (Centro Integral Oncológico HM Clara Campal) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Pajares, María J. (Universidad de Navarra) ;
Suárez, Cristina (Hospital Universitari Vall d'Hebron) ;
Colomer, Ramon (Hospital Universitario de la Princesa (Madrid)) ;
Montuenga, Luis M. (Universidad de Navarra) ;
Melero, Ignacio (Universidad de Navarra) ;
Universitat Autònoma de Barcelona
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. [...]
2017 - 10.1016/j.ctrv.2016.12.005
Cancer Treatment Reviews, Vol. 53 (january 2017) , p. 79-97
|
|
|
3.
|
|
8 p, 664.2 KB |
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma : Implications for patient care
/
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Benzaghou, Fawzi (Ipsen Pharma) ;
Taguieva, Naila (Ipsen Pharma) ;
Nguyen, Linh (Exelixis. Inc.) ;
Clary, Douglas O. (Exelixis. Inc.) ;
Jonasch, Eric W. (The University of Texas MD Anderson Cancer Center) ;
Universitat Autònoma de Barcelona
Cabozantinib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of patients with advanced renal cell carcinoma (RCC) at a dose of 60 mg/day. As with other TKIs, cabozantinib is associated with high interpatient variability in drug clearance and exposure that can significantly impact safety and tolerability across a patient population. [...]
2020 - 10.1016/j.ctrv.2020.102062
Cancer Treatment Reviews, Vol. 89 (september 2020) , p. 102062
|
|
|
4.
|
|
28 p, 884.5 KB |
Cabozantinib for the treatment of solid tumors : a systematic review
/
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari "Aldo Moro) ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Viteri, Santiago (UOMI Cancer Center. Clínica Mi Tres Torres) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Martin, Lidia (Ipsen Pharma) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre. Servicio de Oncología Médica)
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. [...]
2022 - 10.1177/17588359221107112
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
5.
|
|
16 p, 1.3 MB |
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
/
Mar, Nataliya (University of California Irvine) ;
Zakharia, Yousef (University of Iowa Hospitals and Clinics) ;
Falcon, Alejandro (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Morales-Barrera, Rafael (Vall d'Hebron Institut d'Oncologia) ;
Mellado, Begona (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Duran, Ignacio (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Oh, Do-Youn (Seoul National University Hospital) ;
Williamson, Stephen K. (University of Kansas Hospital Cancer Center) ;
Gajate, Pablo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Arkenau, Hendrik-Tobias (University College London Cancer Institute) ;
Jones, Robert J. (BUniversity of Glasgow) ;
Teo, Min Yuen (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Turan, Tolga (Pharmacyclics (Estats Units d'Amèrica)) ;
McLaughlin, Robert T. (Pharmacyclics (Estats Units d'Amèrica)) ;
Peltier, Hillary M. (Pharmacyclics (Estats Units d'Amèrica)) ;
Chong, Elizabeth (Pharmacyclics (Estats Units d'Amèrica)) ;
Atluri, Harisha (Pharmacyclics (Estats Units d'Amèrica)) ;
Dean, James P. (Pharmacyclics (Estats Units d'Amèrica)) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
Urothelial carcinoma (UC) is a common type of bladder cancer. Patients with UC that has not improved after previous treatment or has spread to other parts of the body need new treatment options. Ibrutinib is a drug approved for the treatment of blood cancers and chronic graft-versus-host disease. [...]
2023 - 10.3390/cancers15112978
Cancers, Vol. 15 (may 2023)
|
|
|
6.
|
|
9 p, 1.2 MB |
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
/
Fernandez-Perez, María P. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Perez-Navarro, Enrique (Hospital Universitario 12 de Octubre (Madrid)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Conteduca, Vincenza (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Font, Albert (Institut Català d'Oncologia) ;
Vázquez-Estévez, Sergio (H. Universitario Lucus Augusti) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Wetterskog, Daniel (Paul O'Gorman Building) ;
Antonarakis, Emmanuel S. (Johns Hopkins University School of Medicine) ;
Mellado, Begona (Hospital Clínic i Provincial de Barcelona) ;
Fernandez-Calvo, Ovidio (Complejo Hospitalario Universitario Ourense) ;
Méndez-Vidal, María J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Duran, Ignacio (Instituto de Biomedicina de Sevilla) ;
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodriguez Sanchez, Angel (Hospital Universitario de León) ;
Santander, Carmen (Hospital Universitario Miguel Servet (Saragossa)) ;
Sáez, Maria I. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Puente, Javier (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Tudela, Julian (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martínez, Alberto (Biobanco de la región de Murcia) ;
López-Andreo, Maria J. (SAI-IMIB-Universidad de Murcia) ;
Padilla, José (Hospital Universitario Morales Meseguer) ;
Lozano, Rebeca (Instituto de Investigación Biomédica de Málaga) ;
Hervas, David (Instituto de Investigación Sanitaria La Fe) ;
Luo, Jun (Johns Hopkins University School of Medicine) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Attard, Gerhardt (Paul O'Gorman Building) ;
Grande, Enrique (MD Anderson Cancer Center Madrid) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia-UCAM) ;
Universitat Autònoma de Barcelona
There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). We conducted a phase II trial of enzalutamide in first-line chemo-naïve asymptomatic or minimally symptomatic mCRPC and analyzed the prognostic value of TMPRSS2-ERG and other biomarkers, including circulating tumor cells (CTCs), androgen receptor splice variant (AR-V7) in CTCs and plasma Androgen Receptor copy number gain (AR-gain). [...]
2022 - 10.1002/pros.24469
The Prostate, Vol. 83 (december 2022)
|
|
|
7.
|
|
37 p, 420.1 KB |
Cabozantinib combination therapy for the treatment of solid tumors : a systematic review
/
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari 'Aldo Moro') ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas) ;
Martin, Lidia (Ipsen Pharma) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy for the treatment of solid tumors in adults. [...]
2022 - 10.1177/17588359221108691
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
8.
|
|
13 p, 1.1 MB |
Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy
/
Font, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domènech, Montserrat (Medical Oncology Department, Fundació Althaia, 08243 Manresa, Spain) ;
Benítez, Raquel (Centro Nacional de Investigaciones Oncológicas) ;
Rava, Marta (Centro Nacional de Investigaciones Oncológicas) ;
Marqués, Miriam (Centro Nacional de Investigaciones Oncológicas) ;
Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Pineda, Silvia (Centro Nacional de Investigaciones Oncológicas) ;
Domínguez-Rodríguez, Sara (Centro Nacional de Investigaciones Oncológicas) ;
Gago Ramos, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Badal Lafulla, Josep (Pathology Department, Fundació Althaia, 08243 Manresa, Spain) ;
Carrato, Cristina (Universitat Autònoma de Barcelona. Facultat de Medicina) ;
López, Héctor (Urology Department, Fundació Althaia, 08243 Manresa, Spain) ;
Quer, Ariadna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Malats, Núria (Centro de Investigación Biomédica en Red de Cáncer) ;
Real, Francisco X. (Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut)
Background: Platinum-based neoadjuvant chemotherapy (NAC) increases the survival of patients with organ-confined urothelial bladder cancer (UBC). In retrospective studies, patients with basal/squamous (BASQ)-like tumors present with more advanced disease and have worse prognosis. [...]
2020 - 10.3390/cancers12071784
Cancers, Vol. 12 (july 2020)
|
|
|
9.
|
|
10 p, 947.8 KB |
Atezolizumab in locally advanced or metastatic urothelial cancer : a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
/
Sotelo, M. (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Gajate, Pablo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Morales-Barrera, R. (Hospital Universitari Vall d'Hebron) ;
Pérez-Gracia, J. L. (Clínica Universidad de Navarra) ;
Puente, J. (Hospital Clínico San Carlos (Madrid)) ;
Sánchez, P.. (Roche Farma S.A. Medical Department) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Durán, Ignacio (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Universitat Autònoma de Barcelona
The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer (mUC) upon progression to platinum-based chemotherapy worldwide. [...]
2021 - 10.1007/s12094-020-02482-9
Clinical & Translational Oncology, Vol. 23 (2021) , p. 882-891
|
|
|
10.
|
|
9 p, 341.6 KB |
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
/
Conteduca, Vincenza (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wetterskog, Daniel (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Sharabiani, M. T. A. (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Fernandez Perez, M. P. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Jayaram, Anuradha (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Romanel, A. (Università di Trento. Centro di Biologia Integrata) ;
Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Casadio, Valentina (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gurioli, Giorgia (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Font Guiteras, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vazquez Estevez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Mellado, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Fernandez Calvo, O. (Complejo Hospitalario Universitario de Ourense) ;
Méndez Vidal, M. J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Durán, Ignacio (Instituto de Biomedicina de Sevilla) ;
Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodríguez Sánchez, Ángel (Hospital Universitario de León) ;
Santander, C. (Hospital Universitario Miguel Servet (Saragossa)) ;
Sáez, M. I. (Hospital Regional Universitario de Málaga) ;
Puente, J. (Hospital Clínico San Carlos (Madrid)) ;
Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wingate, Anna (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Dearnaley, David (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ;
Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gonzalez-Billalabeitia, Enrique (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Attard, Gerhardt (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Spanish Oncology Genitourinary Group ;
Universitat Autònoma de Barcelona
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]
2017
Annals of oncology, Núm. 28 (2017) , p. 1508-1516
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
